Free Trial
NASDAQ:PODD

Insulet Q2 2025 Earnings Report

Insulet logo
$284.51 -3.76 (-1.30%)
As of 12:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Insulet EPS Results

Actual EPS
N/A
Consensus EPS
$0.93
Beat/Miss
N/A
One Year Ago EPS
N/A

Insulet Revenue Results

Actual Revenue
N/A
Expected Revenue
$612.31 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Insulet Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Insulet Earnings Headlines

Leerink Partnrs Brokers Lower Earnings Estimates for Insulet
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
Insulet FY2025 EPS Estimate Decreased by Leerink Partnrs
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) is a medical device company specializing in the design, development and manufacture of tubeless insulin delivery systems. With a focus on simplifying diabetes management, Insulet markets its flagship Omnipod product line, which includes wearable, disposable insulin pods and accompanying handheld controllers. The company’s mission centers on improving the lives of people with insulin-dependent diabetes through user-friendly, technology-driven solutions.

The Omnipod System consists of a small, waterproof pod that adheres directly to the skin and delivers continuous subcutaneous insulin via preset dosing, along with a personal diabetes manager (PDM) that wirelessly programs and monitors insulin delivery. Insulet has expanded its product portfolio to include the Omnipod DASH® Insulin Management System and the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitoring (CGM) sensors to adjust insulin dosing in real time. The company also provides mobile applications and cloud‐based platforms to support data sharing and remote patient monitoring.

Founded in 2000 and headquartered in Acton, Massachusetts, Insulet went public in 2007 and has since grown into a global organization serving customers across North America, Europe, Australia, Japan and other international markets. Insulet oversees its own manufacturing facilities and collaborates with third‐party partners to ensure a consistent supply of high-quality pods and electronic components. The company invests heavily in research and development to drive next-generation features, enhance user experience and expand indications for its technology.

Under the leadership of President and Chief Executive Officer John Freda, Insulet emphasizes a patient-centric culture and strategic expansion into new geographies and clinical applications. The management team combines expertise in medical technology, regulatory affairs and commercial operations to guide the company’s long-term growth. Through continuous innovation and a commitment to simplifying insulin delivery, Insulet aims to set new standards in diabetes care and support better outcomes for people living with diabetes.

View Insulet Profile

More Earnings Resources from MarketBeat